<DOC>
	<DOCNO>NCT00201864</DOCNO>
	<brief_summary>The purpose trial evaluate time progression woman hormone responsive advanced breast cancer treat combination exemestane fulvestrant .</brief_summary>
	<brief_title>Exemestane Combination With Fulvestrant Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Proven breast cancer Metastatic locally advance breast cancer Hormonally responsive disease define estrogen ( ER ) and/ progesterone receptor ( PR ) positive ( &gt; 10 % stain immunohistochemistry ) Postmenopausal status No 1 prior chemotherapy stage IV metastatic breast cancer allow ECOG ( Eastern Cooperative Oncology Group ) performance status 02 Adequate organ function No prior Exemestane Fulvestrant Uncontrolled intercurrent illness include limited : ongoing active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia myocardial infarction within last 3 month psychiatric illness/social situation would limit compliance study Lymphangitic pulmonary disease ; carcinomatous meningitis , bone marrow metastasis ; rise tumor marker without site metastatic disease . Presence bleed diathesis coagulopathy , patient require coumadin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>Women</keyword>
</DOC>